{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:11:59Z","timestamp":1791994319126,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02639-y","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:28:07Z","timestamp":1776180487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS\/BRAF wild-type metastatic colorectal cancer"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-2044","authenticated-orcid":false,"given":"Benoist","family":"Chibaudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Marie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Luc","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Desram\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Carola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Baba-Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Auby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Line","family":"Garcia-Larnicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Shacham-Shmueli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-0564","authenticated-orcid":false,"given":"Brian Healey","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimery","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"2639_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337\u2013345 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2639_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham, D. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomized phase 3 trial. Lancet Oncol. 14, 1077\u20131085 (2013).","journal-title":"Lancet Oncol."},{"key":"2639_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard, J.-Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023\u20131034 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2639_CR4","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2639_CR5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/annonc\/mdv130","volume":"26","author":"A Passardi","year":"2015","unstructured":"Passardi, A. et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann. Oncol. 26, 1201\u20131207 (2015).","journal-title":"Ann. Oncol."},{"key":"2639_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013\u20132019 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","volume":"385","author":"LHJ Simkens","year":"2015","unstructured":"Simkens, L. H. J. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomized controlled trial of the Dutch Colorectal Cancer Group. Lancet 385, 1843\u20131852 (2015).","journal-title":"Lancet"},{"key":"2639_CR8","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011\u20132019 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408\u20131417 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2639_CR10","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306\u20131315 (2015).","journal-title":"Lancet Oncol."},{"key":"2639_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem, E. et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 33, 692\u2013700 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386\u20131422 (2016).","journal-title":"Ann. Oncol."},{"key":"2639_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","volume":"124","author":"V Heinemann","year":"2021","unstructured":"Heinemann, V. et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomized clinical trial. Br. J. Cancer 124, 587\u2013594 (2021).","journal-title":"Br. J. Cancer"},{"key":"2639_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","volume":"184","author":"D Rossini","year":"2023","unstructured":"Rossini, D. et al. Primary tumor side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomized trials. Eur. J. Cancer 184, 106\u2013116 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2639_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102823","volume":"145","author":"CC Wu","year":"2020","unstructured":"Wu, C. C. et al. Tumor sidedness and efficacy of first-line therapy in patients with RAS\/BRAF wild-type metastatic colorectal cancer: A network meta-analysis. Crit. Rev. Oncol. Hematol. 145, 102823 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2639_CR16","doi-asserted-by":"publisher","first-page":"105749","DOI":"10.18632\/oncotarget.22396","volume":"8","author":"DP Modest","year":"2017","unstructured":"Modest, D. P. et al. Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget 8, 105749\u2013105760 (2017).","journal-title":"Oncotarget"},{"key":"2639_CR17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/onco.13642","volume":"26","author":"F Pietrantonio","year":"2021","unstructured":"Pietrantonio, F. et al. FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in patients with left-sided RAS\/BRAF wild-type metastatic colorectal cancer: a propensity score-based analysis. Oncologist 26, 302\u2013309 (2021).","journal-title":"Oncologist"},{"key":"2639_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna, J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol. 14, 29\u201337 (2013).","journal-title":"Lancet Oncol."},{"key":"2639_CR19","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499\u20133506 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR20","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero, A. F. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2311\u20132319 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR21","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1002\/onco.13591","volume":"26","author":"A Sobrero","year":"2021","unstructured":"Sobrero, A. et al. Extended RAS analysis of the phase III EPIC trial: Irinotecan + Cetuximab versus Irinotecan as second-line treatment for patients with metastatic colorectal cancer. Oncologist 26, e261\u2013e269 (2021).","journal-title":"Oncologist"},{"key":"2639_CR22","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters, M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706\u20134713 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539\u20131544 (2007).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR24","first-page":"81","volume":"14","author":"MA Khattak","year":"2015","unstructured":"Khattak, M. A. et al. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin. Colorectal Cancer 14, 81\u201390 (2015).","journal-title":"Clin. Colorectal Cancer"},{"key":"2639_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"2639_CR26","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2639_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","volume":"109","author":"DP Modest","year":"2019","unstructured":"Modest, D. P., Pant, S. & Sartore-Bianchi, A. Treatment sequencing in metastatic colorectal cancer. Eur. J. Cancer 109, 70\u201383 (2019).","journal-title":"Eur. J. Cancer"},{"key":"2639_CR28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 15, 1065\u20131075 (2014).","journal-title":"Lancet Oncol."},{"key":"2639_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/bjc.2012.545","volume":"108","author":"D Cunningham","year":"2013","unstructured":"Cunningham, D. et al. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br. J. Cancer 108, 493\u2013502 (2013).","journal-title":"Br. J. Cancer"},{"key":"2639_CR30","first-page":"239","volume":"12","author":"JC Bendell","year":"2013","unstructured":"Bendell, J. C. et al. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clin. Colorectal Cancer 12, 239\u2013247 (2013).","journal-title":"Clin. Colorectal Cancer"},{"key":"2639_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/annonc\/mds465","volume":"24","author":"T Andr\u00e9","year":"2013","unstructured":"Andr\u00e9, T. et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann. Oncol. 24, 412\u2013419 (2013).","journal-title":"Ann. Oncol."},{"key":"2639_CR32","doi-asserted-by":"publisher","first-page":"9309","DOI":"10.18632\/oncotarget.7008","volume":"7","author":"V Derang\u00e8re","year":"2016","unstructured":"Derang\u00e8re, V. et al. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. Oncotarget 7, 9309\u20139321 (2016).","journal-title":"Oncotarget"},{"key":"2639_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/14622416.8.4.319","volume":"8","author":"B Vincenzi","year":"2007","unstructured":"Vincenzi, B. et al. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 8, 319\u2013327 (2007).","journal-title":"Pharmacogenomics"},{"key":"2639_CR34","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook, A. P. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317, 2392\u20132401 (2017).","journal-title":"JAMA"},{"key":"2639_CR35","doi-asserted-by":"crossref","unstructured":"Yoshino T., et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial. J. Clin. Oncol. 40, (suppl 17; abstr LBA1) (2022).","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1"},{"key":"2639_CR36","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","volume":"24","author":"MJG Bond","year":"2023","unstructured":"Bond, M. J. G. et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicenter, randomized, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 24, 757\u2013771 (2023).","journal-title":"Lancet Oncol."},{"key":"2639_CR37","doi-asserted-by":"publisher","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.017","volume":"33","author":"MJG Bond","year":"2022","unstructured":"Bond, M. J. G. et al. LBA21 FOLFOX\/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS\/BRAFV600E wild-type tumor: phase III CAIRO5 study of the Dutch Colorectal Cancer Group. Ann. Oncol. 33, S1389 (2022).","journal-title":"Ann. Oncol."},{"key":"2639_CR38","doi-asserted-by":"crossref","unstructured":"Punt, C. J. A. et al. FOLFOXIRI + bevacizumab versus FOLFOX\/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and\/or RAS\/BRAFV600E-mutated primary tumor: phase III CAIRO5 study of the Dutch Colorectal Cancer Group. J. Clin. Oncol. 40, (suppl 17; abstr LBA3506) (2022).","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3506"},{"key":"2639_CR39","doi-asserted-by":"crossref","unstructured":"Stintzing, S. et al. Phase III FIRE-4 study (AIO KRK-0114): evaluation of first-line treatment efficacy of FOLFIRI\/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only. J. Clin. Oncol. 41, (suppl 4; abstr 100) (2023).","DOI":"10.1200\/JCO.2023.41.4_suppl.100"},{"key":"2639_CR40","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.22.01420","volume":"41","author":"S Stintzing","year":"2023","unstructured":"Stintzing, S. et al. FOLFOXIRI plus cetuximab or bevacizumab as first-line treatment of BRAFV600E-mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study. J. Clin. Oncol. 41, 4143\u20134153 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR41","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1200\/JCO.2015.61.2887","volume":"33","author":"DP Modest","year":"2015","unstructured":"Modest, D. P. et al. Impact of subsequent therapies on outcome of the FIRE-3\/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J. Clin. Oncol. 33, 3718\u20133726 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR42","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.3390\/jcm10215166","volume":"10","author":"CC Wu","year":"2021","unstructured":"Wu, C. C. et al. Optimal sequence and second-line systemic treatment of patients with RAS wild-type metastatic colorectal cancer: a meta-analysis. J. Clin. Med 10, 5166 (2021).","journal-title":"J. Clin. Med"},{"key":"2639_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P. & Heinemann, V. The relevance of primary tumor location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur. J. Cancer 70, 87\u201398 (2017).","journal-title":"Eur. J. Cancer"},{"key":"2639_CR44","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold, D. et al. Prognostic and predictive value of primary tumor side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR-directed antibodies in six randomized trials. Ann. Oncol. 28, 1713\u20131729 (2017).","journal-title":"Ann. Oncol."},{"key":"2639_CR45","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","volume":"28","author":"A Bardelli","year":"2010","unstructured":"Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254\u20131261 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00422","volume":"7","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury, S. et al. Transcriptional profiling and consensus molecular subtype assignment to understand response and resistance to anti-epidermal growth factor receptor therapy in colorectal cancer. JCO Precis Oncol. 7, e2200422 (2023).","journal-title":"JCO Precis Oncol."},{"key":"2639_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.22.01423","volume":"41","author":"CM Parseghian","year":"2023","unstructured":"Parseghian, C. M. et al. Resistance mechanisms to anti-epidermal growth factor receptor therapy in RAS\/RAF wild-type colorectal cancer vary by regimen and line of therapy. J. Clin. Oncol. 41, 460\u2013471 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR48","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.19.01254","volume":"37","author":"F Morano","year":"2019","unstructured":"Morano, F. et al. Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J. Clin. Oncol. 37, 3099\u20133110 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR49","doi-asserted-by":"crossref","unstructured":"Shitara, K. et al. Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: a biomarker study of the phase III PARADIGM trial. J. Clin. Oncol. 41, (suppl 4; abstr 11) (2023).","DOI":"10.1200\/JCO.2023.41.4_suppl.11"},{"key":"2639_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1503-7","volume":"15","author":"B Chibaudel","year":"2015","unstructured":"Chibaudel, B. et al. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer 15, 496 (2015).","journal-title":"BMC Cancer"},{"key":"2639_CR51","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1200\/JCO.2006.10.4380","volume":"25","author":"A de Gramont","year":"2007","unstructured":"de Gramont, A. et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J. Clin. Oncol. 25, 3224\u20133229 (2007).","journal-title":"J. Clin. Oncol."},{"key":"2639_CR52","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1634\/theoncologist.2011-0039","volume":"16","author":"B Chibaudel","year":"2011","unstructured":"Chibaudel, B. et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist 16, 1228\u20131238 (2011).","journal-title":"Oncologist"},{"key":"2639_CR53","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2011.35.5867","volume":"29","author":"B Chibaudel","year":"2011","unstructured":"Chibaudel, B. et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy\u2013an Aide et Recherche en Cancerologie Digestive Group Study. J. Clin. Oncol. 29, 4199\u20134204 (2011).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02639-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02639-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02639-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:02:14Z","timestamp":1776186134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02639-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2639"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02639-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}